MDWD
MediWound Ltd.
$12.10
-4.72% 2026-10-20
Healthcare
MDWDSPY
1W
-1.0%
1M
-9.7%
3M
-15.3%
6M
-27.1%
YTD
-34.5%
1Y
-38.5%
Live chart
Loading live chart…
Grades vs sector
MomentumNot enough data yet–
Momentum
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
GrowthNot enough data yet–
Growth
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
ValueNot enough data yet–
Value
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
ProfitabilityNot enough data yet–
Profitability
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
Revisions
Not enough data yet
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
Quality Growth
not ranked (outside this model's universe or screens)
Momentum Top 15not ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
New Highs Growthnot ranked (outside this model's universe or screens)
Conviction 20not in the current book
News
More newsMediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®
GlobeNewswire · Sep 22
Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification
GlobeNewswire · Sep 14
MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · Sep 02
MediWound (MDWD) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 20
Oppenheimer Adjusts Price Target on MediWound to $30 From $32, Keeps Outperform Rating
MT Newswires · Aug 14
Key stats
Market cap$156.2M
P/E (trailing)–
P/E (forward)-5.3
52-week range11.84 – 19.93
Revenue growth (YoY, latest qtr)-45.8%
Dividend yield0.00%
Analyst consensusNone (6)
Mean price target$30.67 (+153%)
Valuation and fundamentals
Valuation & fundamentals
No US-GAAP 10-K/10-Q financials in SEC data (foreign filers report on Form 20-F, often under IFRS).
Earnings
Next report: 2026-11-19 · before open · EPS est -0.73
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-13 | -0.77 | -0.57 | +26.0% |
| 2026-05-27 | -0.66 | -0.23 | +65.3% |
| 2026-03-05 | -0.61 | -0.56 | +8.5% |
| 2025-11-20 | -0.83 | -0.24 | +71.0% |
| 2025-08-14 | -0.57 | -1.23 | -116.5% |
| 2025-05-21 | -0.66 | -0.07 | +89.4% |
| 2025-03-19 | -0.61 | -0.36 | +40.7% |
| 2024-11-26 | -0.44 | -0.98 | -121.0% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $3.1M | -45.8% |
| 2026-03-31 | $1.5M | – |
| 2025-12-31 | $1.9M | – |
| 2025-09-30 | $5.4M | – |
| 2025-06-30 | $5.7M | – |
Analyst actions
Oppenheimer
PT $30
2026-08-14 · main
Outperform → OutperformPT $30
Oppenheimer
PT $32
2026-05-28 · main
Outperform → OutperformPT $32
HC Wainwright & Co.
PT $36
2026-05-28 · reit
Buy → BuyPT $36
HC Wainwright & Co.
PT $36
2025-11-21 · main
Buy → BuyPT $36
HC Wainwright & Co.
PT $31
2025-05-22 · main
Buy → BuyPT $31
HC Wainwright & Co.
PT $25
2025-03-20 · reit
Buy → BuyPT $25
Insider trades
Rubinstein Samuel
$6.7K
Director · 2026-09-01
SELL$6.7K
Rubinstein Samuel
$6.6K
Director · 2026-09-01
BUY$6.6K
Hess Shmuel
$25.2K
COO & Chief Commercial Officer · 2026-08-27
SELL$25.2K
Hess Shmuel
$26.0K
COO & Chief Commercial Officer · 2026-08-27
SELL$26.0K
Hess Shmuel
$24.2K
COO & Chief Commercial Officer · 2026-08-26
SELL$24.2K
Stats refreshed 2026-10-20 18:14:17 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.